Trading at 8th percentile valuation despite beating earnings 82% of quarters - Graham would recognize this margin of safety.
Spent $4.6B buying shares at $289 that now trade at $155—PepsiCo's predictable earnings machine works better than its capital allocation.
What does this company do and how does it make money?
PepsiCo runs a balanced portfolio of snacks and beverages that generates predictable cash flows from mature markets. The company's strength lies not in explosive growth but in its ability to extract steady returns from established brands across diverse geographies.
Five legendary investment frameworks analyzed this company.
Graham sees a 37.6% discount while Buffett yawns at fair value—but when Norges Bank drops $3.0 billion as insiders flee, someone's about to be spectacularly wrong about this 82% earnings beat machine. Tap any framework below to see their complete analysis and investment position.
How much cash does it generate and where does it go?
PepsiCo operates a capital-light model where suppliers effectively finance the business through extended payment terms. Management returns most free cash to shareholders through dividends while maintaining disciplined reinvestment for asset maintenance.
Is the business getting stronger or weaker?
The business demonstrates remarkable consistency rather than momentum — margins hold steady, returns exceed cost of capital, and management delivers on expectations with metronomic precision. This is stability, not acceleration.
What could go wrong and has it survived trouble before?
The primary risk isn't operational fragility but capital allocation timing — management bought high and insiders are selling into institutional accumulation. The business itself proves resilient through cycles, but shareholder returns depend heavily on price paid.
At 19.4x earnings with 2.3% growth, PepsiCo trades like a growth stock but grows like a utility.
Is the stock priced for perfection, fair value, or pessimism?
The market prices PepsiCo for stagnation, not the steady grower it has proven to be. At decade-low valuation multiples with growth expectations below current delivery, the setup favors patient capital willing to collect dividends while waiting for perception to catch reality.
Analysis applies published investment frameworks to publicly available financial data. Educational purposes only. Not financial advice.